Analysis of data from the SMArtCARE registry demonstrated that nusinersen treatment positively affected motor function over a 38-month period in
Spinal Muscular Atrophy
Spinraza (nusinersen) has been approved by China’s National Medical Product Administration (NMPA) for the treatment of the spinal muscular atrophy
A 7-year-old patient with spinal muscular atrophy (SMA) from South Africa, received our adult stem cell treatment recently.
Is Stem Cell Therapy Right For Me?